

API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/EDMF	DMF
1	Abacavir Sulphate	Anti-Retroviral			√
2	Agomelatine	Anti-Depressant			√ ^α
3	Amisulpride	Anti-Psychotic		√	√ ^α
4	Apixaban	Anti-Coagulant	√*		√
5	Baclofen	Muscle Relaxant	√	√*	√
6	Bilastine (Form I) & (Form II)	Anti Histamine	√*	√	√ ^α , √ ^β
7	Brimonidine Tartrate	Anti-Glaucoma	√	√	√ ^β
8	Carvedilol	Anti-Hypertensive		√	√ ^β
9	Carvedilol Phosphate	Anti-Hypertensive			√
10	Carbinoxamine Maleate	Anti Histamine	√*		√
11	Cinitapride Hydrogen Tartrate	Prokinetic and antiemetic Agent		√	√ ^α
12	Clomiphene Citrate	Ovulatory Stimulants	√*		√
13	Dapoxetine HCl	Treatment of Premature Ejaculation		√	√ ^α
14	Dapagliflozin Propanediol Monohydrate	Anti Diabetic	√*		√
15	Deferasirox	Iron Chelator	√	√	√ ^α
16	Dolutegravir Sodium	Anti-Retroviral	√*		√
17	Edoxaban Tosylate	Anti-Coagulant			√
18	Epalrestat	Aldose Reductase Inhibitor			√ ^α
19	Eszopiclone	Hypnotic	√	√	√ ^β
20	Ezetimibe	Dyslipidemic Agent	√*		√ ^β
21	Empagliflozin	Anti Diabetic			√
22	Ferric Carboxy Maltose	Treatment of Anemia			√
23	Ferric Maltol	Iron Deficiency			√
24	Finerenone	Cardiovascular			√
25	Flibanserin	Female Aphrodisiac			√
26	Glycopyrrolate	Anti Cholinergic	√*		√

√ Approved || √* Filed/Under-approval || √^β CADIFA || √^α China DMF

API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/EDMF	DMF
27	Hydroxychloroquine Sulfate	Anti Malaria	√*		√
28	Hydroxyzine HCl	Anti Histamine	√	√	√ ^β
29	Hydroxyzine Pamoate	Anti Histamine	√*		√
30	Idrocilamide	Skeletal Muscle Relaxant			√
31	Iloperidone	Anti-Psychotic	√*		√
32	Iron Sorbitol Dextrin Citric Acid Complex	Hematinic			√
33	Iron Sucrose LIQ & POW	Hematinic	√*	√	√
34	Iron Polymaltose	Hematinic			√
35	Itopride HCl	Gastro Prokinetic Agent		√	√
36	Ketorolac Tromethamine	NSAID and Anti-inflammatory	√	√	√ ^β
37	Labetalol Hydrochloride	Anti-Hypertensive	√	√	√
38	Lacosamide	Anti-Convulsant	√*	√	√
39	Lamivudine	Anti-Retroviral	√*		√
40	Lanthanum Carbonate	Phosphate Binder	√		√
41	Levocetirizine Di HCl	Anti Histamine	√	√	√ ^β
42	Levodropropizine	Anti-Tussive		√*	√
43	Levosulpiride	Anti-Psychotic		√*	√
44	Linezolid (Form II) & (Form III)	Anti-Bacterial	√	√	√ ^α , √ ^β
45	Linagliptin	Anti Diabetic	√*		√
46	Lopinavir	Anti-Retroviral			√
47	Losartan Potassium	Anti-Hypertensive	√*	√	√
48	Mavacamten	Treatment of Heart Pain (OHCM)	√*		√
49	Meclizine HCl	Anti Histamine	√	√	√ ^β
50	Meprobamate	Anti-Anxiety	√		√
51	Modafinil	Anti-Depressant	√	√*	√
52	Mosapride Citrate Dihydrate	Gastro Prokinetic Agent			√ ^α

* OHCM-Obstructive Hypertrophic Cardiomyopathy.

√ Approved || √* Filed/Under-approval || √^β CADIFA || √^α China DMF

Viyash Life Sciences Private Limited and its subsidiaries respect the intellectual property rights of others. No information in this catalog (including any reference to any product or service) constitutes an offer for sale of products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions. Wherever such regulatory exemptions exist, the buyer should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/EDMF	DMF
53	Olmesartan Medoxomil	Anti-Hypertensive	√*	√*	√
54	Ondansetron HCl Dihydrate	Anti Emetic		√	√ ^β
55	Otilonium Bromide	Irritable Bowel Syndrome (IBS)	√*		√ ^β
56	Phentermine HCl	Anorexic	√		√ ^β
57	Pregabalin	Anti-Convulsant		√*	√
58	Prucalopride Succinate	Gastrointestinal Prokinetic	√	√	√ ^α
59	Racecadotril	Anti Diarrhea		√	√ ^β
60	Ritonavir	Anti-Retroviral			√
61	Rivaroxaban	Anti-Coagulant	√	√	√ ^β
62	Selexipag IH	Treatment of Pulmonary Hypertension			√
63	Sertraline HCl (Form-I & Form II)	Anti-Depressant	√*	√	√
64	Sucroferric Oxyhydroxide	Treatment of Hyperphosphatemia	√*		√ ^α
65	Tamsulosin HCl	Treatment of Benign Prostatic Hyperplasia (BPH)			√
66	Tapentadol HCl (Form-A)	Analgesic & Anti-Inflammatory		√	√ ^β
67	Tapentadol Phosphate	Analgesic & Anti-Inflammatory		√	√
68	Thalidomide	Immunomodulator		√	√
69	Tenofovir Disoproxil Fumarate	Anti-Retroviral	√*		√
70	Ticagrelor	Anti-Platelet	√*	√	√
71	Tizanidine HCl	Muscle Relaxant	√	√	√ ^α , √ ^β
72	Tofisopam	Anti-Anxiety		√	√
73	Vilazodone	Anti-Depressant	√*		√ ^β
74	Viloxazine HCl	Treatment of ADHD	√*		√ ^β
75	Vonoprazan Fumarate	Anti-Ulcer	√*		√ ^β
76	Vortioxetine HBr	Anti-Depressant	√*	√	√ ^β

√ Approved || √* Filed/Under-approval || √^β CADIFA || √^α China DMF

UNDER DEVELOPMENT

S.No	APIs	DRUG CATEGORY
1	5-Fluoro Uracil	Anti-Neoplastic
2	Alectinib	Anti-Neoplastic
3	Abemaciclib	Anti-Neoplastic
4	Avapritinib	Anti-Neoplastic
5	Dabrafenib	Anti-Neoplastic
6	Lisdexamfetamine Dimesylate	Treatment of ADHD
7	Mirogabalin	Treatment of Neuropathic Pain
8	Mirdametinib	Treatment of Neurofibrosis (NF1)

S.No	APIs	DRUG CATEGORY
9	Resmetirom	Treatment of NASH
10	Ruxolitinib Phosphate/ HCl	Treatment of Myelofibrosis and Vitiligo
11	Seladelpar	Treatment of Primary Biliary Cholangitis (PBC)
12	Sparsentan	Treatment of Kidney Disease
13	Tucatinib	Anti-Neoplastic
14	Vibegron	Treatment of Overactive Bladder
15	Venetoclax	Anti-Neoplastic
16	Xanomeline Tartrate	CNS

* ADHD - Attention Deficit Hyperactivity Disorder
* NASH - Nonalcoholic Steatohepatitis

PIPELINE

S.No	APIs	DRUG CATEGORY
1	Ademetionine	Treatment of Liver Disorder, Osteoarthritis and Depression
2	Atogepant	Anti-Migraine
3	Etripamil	Anti-Arrhythmic
4	Gepotidacin	Anti-Bacterial
5	Rimegepant	Anti-Migraine

S.No	APIs	DRUG CATEGORY
6	Iptacopan	Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
7	Obicetrapib	Dyslipidemic Agent
8	Olaparib	Anti-Neoplastic
9	Pitolisant	Treatment of Narcolepsy
10	Sod. Zirconium Cyclosilicate	Potassium Binder
11	Trofinetide	Treatment of Rett Syndrome

Viyash Life Sciences Private Limited and its subsidiaries respect the intellectual property rights of others. No information in this catalog (including any reference to any product or service) constitutes an offer for sale of products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions. Wherever such regulatory exemptions exist, the buyer should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.